Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 05.10.2026 1 Adv Mater 2 Adv Sci (Weinh) 3 Anticancer Res 1 Asian Pac J Cancer Prev 1 Biomed Chromatogr 2 Biomedicines 1 bioRxiv 2 BJU Int 1 BMJ Case Rep 1 Br J Cancer 1 Br J Radiol 1 Cancers (Basel) 1 Clin Cancer Res 1 Curr Med Chem 1 Eur J Radiol 4 Eur Urol 1 Eur Urol Focus 1 Eur Urol Oncol 1 Eur Urol Open Sci 1 Fr J Urol 1 Front Cell Dev Biol 2 Front Immunol 2 Front Oncol 1 Hinyokika Kiyo 1 IJU Case Rep 1 Int J Clin Oncol 1 Int J Mol Sci 1 Int J Nanomedicine 2 Int Urol Nephrol 1 J Biomed Mater Res A 2 J Cancer 1 J Clin Med 1 J Endourol 1 J Geriatr Oncol 1 J Hematop 1 J Med Internet Res 1 J Surg Case Rep 1 J Urol 1 JAMA Netw Open 1 JCO Precis Oncol 1 medRxiv 1 Minerva Urol Nephrol 1 Nat Rev Urol 1 Nurs Open 1 Scand J Urol 1 Support Care Cancer 13 Urol Clin North Am 4 Urol Oncol 1 Urologia 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Mater

1. ZHANG K, Li H, Ma Z, Yu Y, et al
   Metabolic Reprogramming by Engineered Probiotics Potentiates Tumor Chemodynamic Immunotherapy.
   Adv Mater. 2026;38:e74353.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. 
   Correction to "Gut Parabacteroides distasonis-Derived Indole-3-Acetic Acid Promotes Phospholipid Remodeling and Enhances Ferroptosis Sensitivity via the AhR?FASN Axis in Bladder Cancer".
   Adv Sci (Weinh). 2026 Sep 27:e77485. doi: 10.1002/advs.77485.
   PubMed        
   
   
3. WANG L, Liu X, Zhu T, Su Z, et al
   Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer.
   Adv Sci (Weinh). 2026 Sep 27:e77833. doi: 10.1002/advs.77833.
   PubMed         Abstract available
   
   

   
   Anticancer Res

4. KANEKO GO, Igarashi D, Morita M, Tsubota S, et al
   Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma.
   Anticancer Res. 2026;46:5715-5727.
   PubMed         Abstract available
   
   
5. FUKUSHIMA H, Yoshida S, Yajima S, Hirakawa A, et al
   Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.
   Anticancer Res. 2026;46:5729-5735.
   PubMed         Abstract available
   
   
6. WAKAMIYA T, Iwagami S, Enyo N, Shibano S, et al
   Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study.
   Anticancer Res. 2026;46:5639-5650.
   PubMed         Abstract available
   
   

   
   Asian Pac J Cancer Prev

7. MOHAMMED MS, Abouhashim NS, Elfeky MA
   Evaluation of GATA3 and HER-2 Immunohistochemical Expression as Prognostic Markers in Urothelial Carcinoma of the Urinary Bladder.
   Asian Pac J Cancer Prev. 2026;27:3273-3279.
   PubMed         Abstract available
   
   

   
   Biomed Chromatogr

8. JAMBALE U, Thimmappa SC
   Phytochemical Profiling, Antioxidant Activity and Cytotoxic Potential of Chloroxylon swietenia DC. Stem Extracts Against Bladder Cancer Cell Lines.
   Biomed Chromatogr. 2026;40:e70616.
   PubMed         Abstract available
   
   

   
   Biomedicines

9. SZACHNIEWICZ M, Baran M, Gagat M, Halas-Wisniewska M, et al
   Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells.
   Biomedicines. 2026;14:2037.
   PubMed         Abstract available
   
   
10. BILYALOV A, Kotov A, Bodunova N, Zingerenko M, et al
    Molecular Classifications and Candidate Biomarkers for Personalizing BCG Therapy in Non-Muscle-Invasive Bladder Cancer.
    Biomedicines. 2026;14:2098.
    PubMed         Abstract available
    
    

    
    bioRxiv

11. DEITER CS, de Jong FC, Olislagers M, Jordan KR, et al
    Stromal innervation is prognostic in non-muscle-invasive bladder cancer and predicted by a distinct microenvironmental transcriptomic signature.
    bioRxiv [Preprint]. 2026 Sep 22:2026.09.21.751588.
    PubMed         Abstract available
    
    

    
    BJU Int

12. ESCRIG JLD, Black P, Inokuchi J, Kulkarni G, et al
    Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey.
    BJU Int. 2026 Oct 2. doi: 10.1111/bju.70480.
    PubMed         Abstract available
    
    
13. TOUMAZOS K, Bell S, Spencer K, Nakagawa D, et al
    Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.
    BJU Int. 2026 Sep 28. doi: 10.1111/bju.70461.
    PubMed         Abstract available
    
    

    
    BMJ Case Rep

14. ASLAM N, Kafagi AH, Khela A, Montague R, et al
    Metastatic muscle invasive bladder cancer in pregnancy.
    BMJ Case Rep. 2026;19:e275274.
    PubMed         Abstract available
    
    

    
    Br J Cancer

15. GUERRERO QUILES C, Abumanhal-Masarweh H, G Abalos J, Lodhi T, et al
    A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer.
    Br J Cancer. 2026 Sep 26. doi: 10.1038/s41416-026-03603.
    PubMed         Abstract available
    
    

    
    Br J Radiol

16. HUANG W, Fu W, Zhang X, Sun H, et al
    Validation and predictive modeling of a portable bladder scanner for precision bladder management in pelvic radiotherapy.
    Br J Radiol. 2026;99:2155-2163.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

17. PALACKA P, Kovacova Ilijew H, Mikolaskova I, Suchankova M, et al
    The Role of Circulating Extracellular DNA in Patients with Bladder Cancer: Clinical Associations and Exploratory Links with Heart Rate Variability.
    Cancers (Basel). 2026;18:2952.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

18. MAENOSONO R, Nishimura K, Tsujino T, Yoshikawa Y, et al
    Multiplex Immunofluorescence-defined CXCL13-associated TLS-like Niches Predict Outcome in Bladder Cancer.
    Clin Cancer Res. 2026 Sep 29. doi: 10.1158/1078-0432.CCR-26-1878.
    PubMed         Abstract available
    
    

    
    Curr Med Chem

19. SHAIKH AN, Ginayatova I, Malikova I, Kriajevska M, et al
    Novel Approaches in Bladder Cancer Diagnosis and Treatment.
    Curr Med Chem. 2026 Sep 29. doi: 10.2174/0109298673474262260909061628.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

20. ASLAN S, Eryuruk U, Park SY, Arita Y, et al
    VI-RADS and beyond in bladder MRI: a pictorial review of quality control, response assessment, and artificial intelligence.
    Eur J Radiol. 2026;204:113114.
    PubMed         Abstract available
    
    

    
    Eur Urol

21. SCILIPOTI P, Montorsi F
    Re: Matthew D. Galsky and Andrea Necchi. Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.07.014.
    Eur Urol. 2026 Sep 26:S0302-2838(26)02418-8. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
22. SLUSARCZYK A, Uleri A, Radziszewski P, Pradere B, et al
    Re: Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.e
    Eur Urol. 2026 Oct 1:S0302-2838(26)02070-1. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
23. DING D, Wei W, Chen H, Tan W, et al
    Reply to Pierre-Etienne Gabriel and Evanguelos Xylinas's Letter to the Editor re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur
    Eur Urol. 2026 Oct 1:S0302-2838(26)02000-2. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
24. DAVIS LE, Basourakos SP, Calaway AC
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Oct 1:S0302-2838(26)01999-8. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Focus

25. ROESSLER N, Miszczyk M, Miyajima K, Alfarhan AR, et al
    The Influence of Urinary Diversion Type on Body Image and Decision Regret Following Radical Cystectomy: A Systematic Review.
    Eur Urol Focus. 2026;12:785-795.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

26. GONTERO P, Babjuk M
    Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Exp
    Eur Urol Oncol. 2026 Sep 26:S2588-9311(26)00243.
    PubMed        
    
    

    
    Eur Urol Open Sci

27. SCHOLTES MP, Koedoot E, Ceton LJ, Sijsenaar TJP, et al
    Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.
    Eur Urol Open Sci. 2026;93:3-11.
    PubMed         Abstract available
    
    

    
    Fr J Urol

28. BIEST AMD, Xylinas E, Gabriel PE
    SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL AFTER BCG FAILURE NON-MUSCLE INVASIVE BLADDER CANCER: ONCOLOGICAL OUTCOMES AND SAFETY PROFILE.
    Fr J Urol. 2026 Sep 28:103229. doi: 10.1016/j.fjurol.2026.103229.
    PubMed         Abstract available
    
    

    
    Front Cell Dev Biol

29. JI Y, Zhang Y, Liu X, Lv Z, et al
    Single-cell and bulk transcriptomic analyses define an IFI27-centered interferon-response epithelial state in bladder cancer and its transcriptional response to irradiation.
    Front Cell Dev Biol. 2026;14:1920354.
    PubMed         Abstract available
    
    

    
    Front Immunol

30. WU X, Sun T, Liu Z
    Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer.
    Front Immunol. 2026;17:1891824.
    PubMed         Abstract available
    
    
31. WU S, Fu S, Shi H, Gong Y, et al
    Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.
    Front Immunol. 2026;17:1920567.
    PubMed         Abstract available
    
    

    
    Front Oncol

32. LI J, Tang C, Yang L, Song C, et al
    ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025.
    Front Oncol. 2026;16:1906152.
    PubMed         Abstract available
    
    
33. MAO D, Chen R, Guan F, Sun J, et al
    Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1876253.
    PubMed         Abstract available
    
    

    
    Hinyokika Kiyo

34. SOMEYA R, Tanaka E, Yamazak M, Yokoi T, et al
    [URINARY RETENTION FOLLOWING TRANSURETHRAL RESECTION OF THE BLADDER TUMOR].
    Hinyokika Kiyo. 2026;72:269-271.
    PubMed         Abstract available
    
    

    
    IJU Case Rep

35. NAKANISHI Y, Kawashima Y, Shinohara M, Hagiwara K, et al
    Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report.
    IJU Case Rep. 2026;9:e70270.
    PubMed         Abstract available
    
    

    
    Int J Clin Oncol

36. SAITO R, Sano T, Kanno T, Aizawa R, et al
    Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.
    Int J Clin Oncol. 2026;31:2114-2125.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

37. TATAR AC, Voidazan S, Raicea A, Popelea MC, et al
    Immunohistochemistry-Based Molecular Classification of Muscle-Invasive Bladder Urothelial Carcinoma: Survival Trends Across Molecular Subtypes.
    Int J Mol Sci. 2026;27:8082.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

38. DING W, Zhang X, Wu H, Zhou C, et al
    Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment.
    Int J Nanomedicine. 2026;21:616713.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

39. LEE JH, Lee CU, Song W, Sung HH, et al
    Role of neoadjuvant chemotherapy in micropapillary urothelial carcinoma: a multi-institutional analysis from the Korean Bladder Cancer Research Group.
    Int Urol Nephrol. 2026 Oct 1. doi: 10.1007/s11255-026-05412.
    PubMed         Abstract available
    
    
40. HAYASHI Y, Yamashita R, Sakura Y, Sugino T, et al
    Concurrent extension of bladder cancer to the intramural ureter and prostatic urethra increases the risk of urethral cancer in patients undergoing radical cystectomy.
    Int Urol Nephrol. 2026 Sep 26. doi: 10.1007/s11255-026-05408.
    PubMed         Abstract available
    
    

    
    J Biomed Mater Res A

41. LUO H, Liu X, Du Y
    Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer.
    J Biomed Mater Res A. 2026;114:e70164.
    PubMed         Abstract available
    
    

    
    J Cancer

42. LI S, Peng H, Li G, Wan Z, et al
    A candidate PPARgamma to GPX4 axis in ferroptosis suppression and platinum resistance in bladder cancer: evidence appraisal and a testable research agenda.
    J Cancer. 2026;17:1797-1807.
    PubMed         Abstract available
    
    
43. ZHU Y, Shang J, Zhang X, Tu S, et al
    Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer.
    J Cancer. 2026;17:1720-1732.
    PubMed         Abstract available
    
    

    
    J Clin Med

44. TICHIL BP, Besleaga A, Gheorghiu I, Chiorean AD, et al
    Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study.
    J Clin Med. 2026;15:7117.
    PubMed         Abstract available
    
    

    
    J Endourol

45. ERAKY A, Mehrazin R, Tillu N, Wagaskar VG, et al
    The Hood Technique for Robot-Assisted Radical Cystoprostatectomy with Intracorporeal Neobladder.
    J Endourol. 2026;40:1156-1163.
    PubMed         Abstract available
    
    

    
    J Geriatr Oncol

46. ERNANDEZ J, Xiang L, Adler R, Hsu J, et al
    Significance of dementia and frailty on postoperative care trajectories and burden among older adults undergoing radical cystectomy for bladder cancer.
    J Geriatr Oncol. 2026;18:104389.
    PubMed         Abstract available
    
    

    
    J Hematop

47. KAUR N, Aravind A, Jain SP
    Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature.
    J Hematop. 2026;19:59.
    PubMed         Abstract available
    
    

    
    J Med Internet Res

48. FRISCH D, Fronstin M, Zema C
    Agentic AI for Clinical Outcomes Research, Population Health Management Analyses With Large Administrative Databases, and Generating Epidemiological Estimates of Diseases: Feasibility and Validation Study.
    J Med Internet Res. 2026;28:e100284.
    PubMed         Abstract available
    
    

    
    J Surg Case Rep

49. GOUNNI MY, Bourimi C, Tariqi R, Bakouch M, et al
    A false alarm in bladder cancer surveillance: eosinophilic cystitis after intravesical BCG instillations.
    J Surg Case Rep. 2026;2026:rjag855.
    PubMed        
    
    

    
    J Urol

50. GAFFNEY CD, Alam SM, Wald G, Sjoberg D, et al
    A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guerin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2026 Oct 1:101097JU0000000000005324. doi: 10.1097/JU.0000000000005324.
    PubMed         Abstract available
    
    

    
    JAMA Netw Open

51. WU Y, Han W, Xiong S, He Y, et al
    Urine Methylation Test for Urothelial Cancer Diagnosis and Surveillance.
    JAMA Netw Open. 2026;9:e2636786.
    PubMed         Abstract available
    
    

    
    JCO Precis Oncol

52. STOJKOVA O, Borcsok J, Sztupinszki Z, Diossy M, et al
    Identification of an ERCC2 Mutation-Associated Mutational Signature of Nucleotide Excision Repair Deficiency in Targeted Panel Sequencing Data.
    JCO Precis Oncol. 2026;10:e2600329.
    PubMed         Abstract available
    
    

    
    medRxiv

53. LI R, Linscott J, Murthy P, Rose K, et al
    Evaluation of Urinary Circulating Tumor DNA to Detect Minimal Residual Disease in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.
    medRxiv [Preprint]. 2026 Sep 11:2026.09.09.26362655.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

54. ERMIS O, Aybal HC, Yuan CY, Tozsin A, et al
    Simultaneous surgery for NMIBC and BOO: evaluating surgical safety to oncological benefit.
    Minerva Urol Nephrol. 2026;78:484-497.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

55. CONTIERI R, Gontero P, Hurle R, Afferi L, et al
    Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.
    Nat Rev Urol. 2026;23:691-696.
    PubMed         Abstract available
    
    

    
    Nurs Open

56. ACQUISTAPACE E, Bernardini B, Piccioni F, Pastore M, et al
    Exploring the Role of the Nurse Case Manager in the Care Experience of Patients Undergoing Radical Cystectomy: A Qualitative Study.
    Nurs Open. 2026;13:e70821.
    PubMed         Abstract available
    
    

    
    Scand J Urol

57. LINGEFELT S, Nystrand V, Alamdari F, Svensson J, et al
    No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer.
    Scand J Urol. 2026;61:230-238.
    PubMed         Abstract available
    
    

    
    Support Care Cancer

58. ZHANG M, Chen Z, Chen Y, Zhou Y, et al
    Longitudinal data on health-related quality of life and its association with time to readmission in bladder perfusion patients.
    Support Care Cancer. 2026;34:1032.
    PubMed         Abstract available
    
    

    
    Urol Clin North Am

59. SADIQ S, Nativ O, Ritch CR
    Open and Robotic Radical Cystectomy for Muscle-Invasive Bladder Cancer: Techniques, Outcomes, and Evidence.
    Urol Clin North Am. 2026;53:551-559.
    PubMed         Abstract available
    
    
60. GHASEMZADEH A, Bochner BH
    What Is the Proper Extent of Lymph Node Dissection During a Radical Cystectomy for Bladder Cancer?
    Urol Clin North Am. 2026;53:561-569.
    PubMed         Abstract available
    
    
61. MCSWEENEY ST, Aydogdu C, Bole R, Bukavina L, et al
    Sexual Function Preservation After Cystectomy.
    Urol Clin North Am. 2026;53:571-582.
    PubMed         Abstract available
    
    
62. CHUNG R, Zibelman MR, Wong JK, Kutikov A, et al
    Advancements in Bladder-Sparing Strategies for Muscle-Invasive Bladder Cancer: A Comprehensive Review.
    Urol Clin North Am. 2026;53:539-549.
    PubMed         Abstract available
    
    
63. ATIQ SO, Miller EJ, Anker JF, Galsky MD, et al
    Adjuvant Therapy in Patients after Cystectomy.
    Urol Clin North Am. 2026;53:593-600.
    PubMed         Abstract available
    
    
64. ZHU A, Eraky A, Gabriel PE, Sfakianos JP, et al
    The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:601-612.
    PubMed         Abstract available
    
    
65. DUBIC MG, Ward MC, Riggs S
    Trimodal Therapy for Muscle Invasive Bladder Cancer: An Update on Current Practices and Future Directions.
    Urol Clin North Am. 2026;53:613-624.
    PubMed         Abstract available
    
    
66. ROESSLER N, von Deimling M, Miszczyk M, Vetterlein MW, et al
    The Role of Surgery in Locally Advanced and Oligometastatic Bladder Cancer.
    Urol Clin North Am. 2026;53:625-634.
    PubMed         Abstract available
    
    
67. SUPERDOCK M, Iyer G, Milowsky MI
    New and Novel Agents for Advanced Bladder Cancer.
    Urol Clin North Am. 2026;53:635-648.
    PubMed         Abstract available
    
    
68. LOUGHLIN KR
    Muscle-Invasive Bladder Cancer: The Marriage of Surgery and Science.
    Urol Clin North Am. 2026;53:xiii-xiv.
    PubMed        
    
    
69. CLARK PE
    Management of Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:xv.
    PubMed        
    
    
70. EBER J, Matulay JT
    Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: Current Evidence, Evolving Strategies, and Future Directions.
    Urol Clin North Am. 2026;53:517-526.
    PubMed         Abstract available
    
    
71. BRITTON CJ, Galloway LAS, Luckenbaugh AN
    Prehabilitation and Patient Optimization for Cystectomy.
    Urol Clin North Am. 2026;53:527-538.
    PubMed         Abstract available
    
    

    
    Urol Oncol

72. ERYILMAZ R, Keles MF, Aslan R, Huyut Z, et al
    Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.
    Urol Oncol. 2026;44:939-945.
    PubMed         Abstract available
    
    
73. MANTZ L, Zhu A, Mercaldo ND, Marquardt PA, et al
    Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer.
    Urol Oncol. 2026;44:946-959.
    PubMed         Abstract available
    
    
74. MORGAN TM, Wang CY, Yapici HO, Lilley J, et al
    Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy.
    Urol Oncol. 2026;44:960-967.
    PubMed         Abstract available
    
    
75. HAU AM, Nakasaki M, Nakashima K, Krish G, et al
    Corrigendum to "Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition" Volume 35, Issue 10, October 2017, Pages 593-599.
    Urol Oncol. 2026 Oct 1:S1078-1439(26)00729-5. doi: 10.1016/j.urolonc.2026.
    PubMed        
    
    

    
    Urologia

76. HEER R, Farrokhi M
    Global trends and hotspots in bladder cancer: A bibliometric analysis (2016-2025).
    Urologia. 2026 Sep 28:3915603261483766. doi: 10.1177/03915603261483766.
    PubMed         Abstract available
    
    

    
    World J Urol

77. SCILIPOTI P, Slusarczyk A, Subiela JD, Longoni M, et al
    Surrogacy of intermediate clinical endpoints for overall survival in BCG-naive high-risk non-muscle-invasive bladder cancer.
    World J Urol. 2026;44:721.
    PubMed         Abstract available
    
    
78. ELMASMOUDI J, Merseburger AS
    Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.
    World J Urol. 2026;44:722.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum